The antiandrogen withdrawal syndrome in relapsed prostate cancer Conference Paper
| Authors: | Scher, H. I.; Kolvenbag, G. J. C. M. |
| Title: | The antiandrogen withdrawal syndrome in relapsed prostate cancer |
| Conference Title: | New Avenues and Perspectives in the Management of Advanced Prostate Cancer |
| Abstract: | Evolving data suggest that palliation of relapsed prostate cancer can be achieved by the selective discontinuation of agents that act via steroid hormone receptors. Clinical benefit has been observed following the withdrawal of flutamide (Eulexin®, Schering-Plough International), bicalutamide (Casodex®, Zeneca Ltd), oestrogens, progestational agents and retinoids. For patients with progression of disease while receiving these drugs, a period of observation after withdrawal should be considered before further therapy is initiated. |
| Keywords: | cancer recurrence; conference paper; cancer palliative therapy; palliative care; estrogen; withdrawal syndrome; prostate cancer; prostate-specific antigen; prostatic neoplasms; disease progression; androgen antagonists; antiandrogen; bicalutamide; flutamide; antineoplastic agents, hormonal; steroid receptor; retinoid; gestagen; combined androgen blockade; antiandrogen therapy; antiandrogen withdrawal syndrome; humans; human; male; priority journal; bicalutamide (casodex®); flutamide (eulexin®) |
| Journal Title | European Urology |
| Volume: | 31 |
| Issue: | Suppl. 2 |
| Conference Dates: | 1996 Sep 1 |
| Conference Location: | Paris, France |
| ISBN: | 0302-2838 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 1997-02-01 |
| Start Page: | 3 |
| End Page: | 7; discussion 24-27 |
| Language: | English |
| PUBMED: | 9074903 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Conference Paper -- Export Date: 17 March 2017 -- Source: Scopus |
